Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Insulin Detemir Titration Algorithms After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment With or Without Other Anti-diabetic Drugs (OADs)
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 46
- Registration Number
- NCT01868542
- Locations
- 🇰🇷
Novo Nordisk Investigational Site, Daejeon, Korea, Republic of
Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- Drug: insulin degludec/insulin aspart 40Drug: insulin degludec/insulin aspart 30Drug: insulin degludec/insulin aspart 45Drug: insulin degludec/insulin aspart 55Drug: placebo
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2015-10-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 55
- Registration Number
- NCT01868568
Bioequivalence Between Two Explorative Insulin Degludec Formulations and Between Two Explorative IDegAsp Formulations in Healthy Subjects
Phase 1
Completed
- Conditions
- DiabetesHealthy
- Interventions
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2015-10-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 58
- Registration Number
- NCT01868581
Comparison of Insulin Degludec With Insulin Glargine in Subjects With Type 1 Diabetes Mellitus
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 63
- Registration Number
- NCT01868529
Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects
Phase 1
Completed
- Conditions
- HealthyDiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: placebo
- First Posted Date
- 2013-05-31
- Last Posted Date
- 2014-04-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 170
- Registration Number
- NCT01866748
Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1
- Interventions
- Drug: insulin degludec/insulin aspart 40Drug: insulin degludec/insulin aspart 30Drug: insulin degludec/insulin aspart 50
- First Posted Date
- 2013-05-30
- Last Posted Date
- 2015-10-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 59
- Registration Number
- NCT01865305
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Explorative Formulation of Insulin Degludec
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2013-05-30
- Last Posted Date
- 2015-10-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 64
- Registration Number
- NCT01865279
Investigation of Pharmacodynamic Characteristics of Explorative Formulation of Insulin Degludec in Male Subjects With Type 1 Diabetes
- First Posted Date
- 2013-05-30
- Last Posted Date
- 2015-10-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 36
- Registration Number
- NCT01865318
Comparing the Pharmacodynamics and Pharmacokinetics of Explorative Formulation of Insulin Degludec With Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2013-05-30
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 40
- Registration Number
- NCT01865292
Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Characteristics of Explorative Formulations of Insulin Degludec and IDegAsp 50 in Healthy Japanese Subjects
Phase 1
Completed
- Conditions
- DiabetesHealthy
- Interventions
- First Posted Date
- 2013-05-30
- Last Posted Date
- 2016-01-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 32
- Registration Number
- NCT01865331
© Copyright 2025. All Rights Reserved by MedPath